Product
mFOLFOX6
Aliases
mFOLFOX6 regimen, mFOLFOX6 Regimen
16 clinical trials
20 indications
Indication
Colorectal CancerIndication
Advanced CancerIndication
Stomach CancerIndication
Gastroesophageal Junction CancerIndication
Pancreatic CancerIndication
CancerIndication
Esophageal CancerIndication
Colon CancerIndication
Rectal CancerIndication
Colorectal cancerIndication
Metastatic Colorectal CancerIndication
Pancreatic Ductal AdenocarcinomaIndication
PDACIndication
Gastrointestinal CancerIndication
Stage III Colon CancerIndication
Gastric Cancer Stage IVIndication
Peritoneal CarcinomatosisIndication
Intraperitoneal PaclitaxelIndication
mFOLFOX6Indication
Bile Duct CancerClinical trial
A Randomized Phase 3 Study of MRTX849 in Combination With Cetuximab Versus Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation With Disease Progression On or After Standard First-Line TherapyStatus: Active (not recruiting), Estimated PCD: 2025-02-28
Clinical trial
A Phase I/IIa Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of TST001 Administered as Monotherapy or in Combination With Nivolumab or Standard of Care in Patients With Locally Advanced or Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
A Phase 1/2 Study of Durvalumab and Monalizumab in Adult Subjects With Select Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2021-10-26
Clinical trial
A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer With FGFR2b OverexpressionStatus: Recruiting, Estimated PCD: 2025-08-18
Clinical trial
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, Alone and in Combination With an Anti-PD-1 in Patients With Advanced Solid TumorsStatus: Completed, Estimated PCD: 2022-06-02
Clinical trial
A Randomized, Multicenter, Phase 2 Study to Compare the Efficacy of Panitumumab in Combination With mFOLFOX6 to the Efficacy of Bevacizumab in Combination With mFOLFOX6 in Patients With Previously Untreated, KRAS Wild-Type, Unresectable, Metastatic Colorectal CancerStatus: Completed, Estimated PCD: 2012-05-30
Clinical trial
A Randomized, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of QL1203 and Placebo Respectively Combined With Chemotherapy in Patients With Metastatic Colorectal CancerStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177)Status: Completed, Estimated PCD: 2021-02-19
Clinical trial
A Phase 1a/1b Study of GS-1423, an Anti-CD73-TGFβ-Trap Bifunctional Antibody, as Monotherapy or in Combination With a Chemotherapy Regimen in Subjects With Advanced Solid TumorsStatus: Terminated, Estimated PCD: 2020-10-27
Clinical trial
Randomized Phase 2 Study of Valproic Acid in Combination With Bevacizumab and Oxaliplatin/Fluoropyrimidine Regimens in Patients With Ras-mutated Metastatic Colorectal CancerStatus: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
A Platform Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid TumorsStatus: Recruiting, Estimated PCD: 2027-05-15
Clinical trial
mFOLFOXIRI Versus mFOLFOX6 as Adjuvant Chemotherapy for Locally Advanced Colorectal Cancer Patients After Preoperative Treatment With Oxaliplatin (FANTASTIC): a Multicenter, Phase 3 Randomized Controlled TrialStatus: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
Colon Adjuvant Chemotherapy Based on Evaluation of Residual DiseaseStatus: Recruiting, Estimated PCD: 2029-03-10
Clinical trial
Safety and Efficacy of Intraperitoneal Paclitaxel in Gastric Cancer Patients With Peritoneal Metastasis Receiving Systemic ChemotherapyStatus: Completed, Estimated PCD: 2023-08-31
Clinical trial
Randomized Phase II Study for Evaluation of Efficacy and Safety of Maintenance Treatment With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction Treatment With mFOLFOX6 Plus Panitumumab and Re-induction With mFOLFOX6 Plus Panitumumab in Case of Progression for First-line Treatment of Patients With Metastatic Colorectal CancerStatus: Completed, Estimated PCD: 2023-02-18
Clinical trial
A Phase Ib/II Single-arm Study Evaluating the Safety and Efficacy of Combined Immunotherapy With mFOLFOX6, Bevacizumab and Atezolizumab in Advanced-stage Biliary Tract CancerStatus: Recruiting, Estimated PCD: 2024-06-01